Korean J Hematol.  2011 Dec;46(4):253-257. 10.5045/kjh.2011.46.4.253.

Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia

• Choi SY
• Kim I
• Kim NJ
• Lee SA
• Choi YA
• Bae JY
• Kwon JH
• Choe PG
• Park WB
• Yoon SS
• Park S
• Kim BK
• Oh MD

• KMID: 2251986
• DOI: http://doi.org/10.5045/kjh.2011.46.4.253

Abstract

BACKGROUND
The aim of this study is to investigate the hematological manifestations of human immunodeficiency virus (HIV) infection, the risk factors for cytopenia, and the effect of highly active anti-retroviral therapy (HAART) on cytopenia.
METHODS
Medical records of patients treated for HIV at the Seoul National University Hospital from January 2005 to March 2010 were retrospectively reviewed. To determine the impact of HIV itself, we excluded HIV patients who had other conditions that could have resulted in hematological manifestations. Multiple logistic regression analyses were performed to identify risk factors for cytopenia.
RESULTS
A total of 621 cases were investigated, and after exclusion, data of 472 patients were analyzed. The frequency of cytopenia was anemia, 3.0% (14/472); neutropenia, 10.0% (47/472); thrombocytopenia, 2.4% (12/472); lymphopenia, 25.7% (121/470); isolated cytopenia, 11.2% (53/472); and bicytopenia, 2.1% (10/472). The leading risk factor for cytopenia identified by multivariate logistic regression methods was AIDS status at initial presentation. After HAART, cytopenia was reversed in the majority of patients (thrombocytopenia, 100%; neutropenia, 91.1%; and anemia, 84.6%).
CONCLUSION
This study isolated the impact of HIV infection alone on hematologic manifestations and confirmed that these changes were reversible by HAART. Control of the HIV infection will have the main role in the management of hematological manifestations of the virus.

Keyword

HAART; Hematologic manifestations; HIV infection; Risk factor

MeSH Terms

Anemia
Antiretroviral Therapy, Highly Active
HIV
HIV Infections
Humans
Logistic Models
Lymphopenia
Medical Records
Neutropenia
Retrospective Studies
Risk Factors
Thrombocytopenia
Viruses

Reference

1. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood. 1998; 91:1479–1495. PMID: 9473211.

2. Passos AM, Treitinger A, Spada C. An overview of the mechanisms of HIV-related thrombocytopenia. Acta Haematol. 2010; 124:13–18. PMID: 20606410.

3. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998; 91:301–308. PMID: 9414298.

4. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in highincome countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372:293–299. PMID: 18657708.

5. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010; 376:449–457. PMID: 20638120.

6. Firnhaber C, Smeaton L, Saukila N, et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010; 14:e1088–e1092. PMID: 20961784.

7. Nair MP, Schwartz SA. Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2. Clin Diagn Lab Immunol. 2000; 7:101–105. PMID: 10618286.

8. Carbonara S, Fiorentino G, Serio G, et al. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect. 2001; 42:251–256. PMID: 11545567.

9. Scaradavou A. HIV-related thrombocytopenia. Blood Rev. 2002; 16:73–76. PMID: 11914001.

10. Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA. 1986; 256:491–493. PMID: 3088292.

11. Sloand E. Hematologic complications of HIV infection. AIDS Rev. 2005; 7:187–196. PMID: 16425959.

12. Sarcletti M, Quirchmair G, Weiss G, Fuchs D, Zangerle R. Increase of haemoglobin levels by anti-retroviral therapy is associated with a decrease in immune activation. Eur J Haematol. 2003; 70:17–25. PMID: 12631255.

13. Aboulafia DM, Bundow D, Waide S, Bennet C, Kerr D. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. Am J Med Sci. 2000; 320:117–123. PMID: 10981487.

14. Huang SS, Barbour JD, Deeks SG, et al. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000; 30:504–510. PMID: 10722435.

15. Lee JH, Lee EJ, Kim SS, Nam JG, Whang J, Kee MK. Epidemiological characteristics of HIV-infected women in the Republic of Korea: a low HIV prevalence country. J Public Health Policy. 2009; 30:342–355. PMID: 19806074.

16. Lee JH, Kim GJ, Choi BS, et al. Increasing late diagnosis in HIV infection in South Korea: 2000-2007. BMC Public Health. 2010; 10:411. PMID: 20624319.

17. Burbano X, Miguez MJ, Lecusay R, et al. Thrombocytopenia in HIV-infected drug users in the HAART era. Platelets. 2001; 12:456–461. PMID: 11798394.